Steven, S., Oelze, M., Hanf, A., Kröller-Schön, S., Kashani, F., Roohani, S., . . . Daiber, A. (2017). The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats. Redox Biol.
استشهاد بنمط شيكاغوSteven, Sebastian, et al. "The SGLT2 Inhibitor Empagliflozin Improves the Primary Diabetic Complications in ZDF Rats." Redox Biol 2017.
MLA استشهادSteven, Sebastian, et al. "The SGLT2 Inhibitor Empagliflozin Improves the Primary Diabetic Complications in ZDF Rats." Redox Biol 2017.
تحذير: قد لا تكون هذه الاستشهادات دائما دقيقة بنسبة 100%.